Wirsching HG - Search Results

1

Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma.

Wirsching HG, Silginer M, Ventura E, Macnair W, Burghardt I, Claassen M, Gatti S, Wichmann J, Riemer C, Schneider H, Weller M. Wirsching HG, et al. Mol Ther Oncolytics. 2020 Dec 25;20:166-174. doi: 10.1016/j.omto.2020.12.009. eCollection 2021 Mar 26. Mol Ther Oncolytics. 2020. PMID: 33575479 Free PMC article.

2

Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma.

Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbühl N, Hasenbach K, Reifenberger G, Weller M, Tabatabai G. Wirsching HG, et al. Brain. 2014 Feb;137(Pt 2):433-48. doi: 10.1093/brain/awt333. Epub 2013 Dec 18. Brain. 2014. PMID: 24355709 Free article.

3

The management of lomustine overdose in malignant glioma patients.

Wirsching HG, Tritschler I, Palla A, Renner C, Weller M, Tabatabai G. Wirsching HG, et al. Neurooncol Pract. 2014 Dec;1(4):178-183. doi: 10.1093/nop/npu023. Epub 2014 Sep 12. Neurooncol Pract. 2014. PMID: 26034630 Free PMC article.

4

Management of diffusely infiltrating glioma in the elderly.

Wirsching HG, Happold C, Roth P, Weller M. Wirsching HG, et al. Curr Opin Oncol. 2015 Nov;27(6):502-9. doi: 10.1097/CCO.0000000000000236. Curr Opin Oncol. 2015. PMID: 26397765 Free article. Review.

5

Predicting outcome of epilepsy after meningioma resection.

Wirsching HG, Morel C, Gmür C, Neidert MC, Baumann CR, Valavanis A, Rushing EJ, Krayenbühl N, Weller M. Wirsching HG, et al. Neuro Oncol. 2016 Jul;18(7):1002-10. doi: 10.1093/neuonc/nov303. Epub 2015 Dec 18. Neuro Oncol. 2016. PMID: 26683139 Free PMC article.

6

Glioblastoma.

Wirsching HG, Galanis E, Weller M. Wirsching HG, et al. Handb Clin Neurol. 2016;134:381-97. doi: 10.1016/B978-0-12-802997-8.00023-2. Handb Clin Neurol. 2016. PMID: 26948367 Review.

7

The Role of Molecular Diagnostics in the Management of Patients with Gliomas.

Wirsching HG, Weller M. Wirsching HG, et al. Curr Treat Options Oncol. 2016 Oct;17(10):51. doi: 10.1007/s11864-016-0430-4. Curr Treat Options Oncol. 2016. PMID: 27501915 Review.

8

Advances in the molecular genetics of gliomas - implications for classification and therapy.

Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Reifenberger G, et al. Among authors: wirsching hg. Nat Rev Clin Oncol. 2017 Jul;14(7):434-452. doi: 10.1038/nrclinonc.2016.204. Epub 2016 Dec 29. Nat Rev Clin Oncol. 2017. PMID: 28031556 Free article. Review.

9

Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas.

Schneider H, Lohmann B, Wirsching HG, Hasenbach K, Rushing EJ, Frei K, Pruschy M, Tabatabai G, Weller M. Schneider H, et al. Among authors: wirsching hg. Oncotarget. 2017 Aug 3;8(50):87124-87135. doi: 10.18632/oncotarget.19894. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152068 Free PMC article.

10

Copy number profiling across glioblastoma populations has implications for clinical trial design.

Cimino PJ, McFerrin L, Wirsching HG, Arora S, Bolouri H, Rabadan R, Weller M, Holland EC. Cimino PJ, et al. Among authors: wirsching hg. Neuro Oncol. 2018 Sep 3;20(10):1368-1373. doi: 10.1093/neuonc/noy108. Neuro Oncol. 2018. PMID: 29982740 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

51 results

Search Page

Filters